eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
09/09/20
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
08/24/20
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
08/21/20
Eyenovia, Inc. Announces Closing of Offering of Common Stock
Upcoming Events
There are currently no events scheduled.